1. Scrip

AstraZeneca’s Calquence Catches Up With Imbruvica’s CLL Claim

 
• By Leah Samuel

AZ is counting on Calquence’s safety profile to gain ground against AbbVie/J&J’s blockbuster BTK inhibitor Imbruvica.

FDA’s broad approval for AstraZeneca PLC PLC’s Calquence (acalabrutinib) for chronic lymphocytic leukemia and small lymphocytic leukemia for any line of treatment gives the company the best shot possible at gaining share from AbbVie Inc./Johnson & Johnson’s market leading Imbruvica (ibrutinib).

The US Food & Drug Administration cleared AstraZeneca’s BTK inhibitor for the CLL/SLL indication on 21 November, a review expedited...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?